HOUSE 1570116th CongressReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Removing Barriers to Colorectal Cancer Screening Act of 2020

Last Action: 12/10/2020

Actions

2020-12-10Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2020-12-09The title of the measure was amended. Agreed to without objection.
2020-12-09Motion to reconsider laid on the table Agreed to without objection.
2020-12-09On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7083-7084)
2020-12-09Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
2020-12-09DEBATE - The House proceeded with forty minutes of debate on H.R. 1570.
2020-12-09Considered under suspension of the rules. (consideration: CR H7083-7086)
2020-12-09Mr. Pallone moved to suspend the rules and pass the bill, as amended.
2019-03-08Sponsor introductory remarks on measure. (CR H2608)
2019-03-07Referred to the Subcommittee on Health.
2019-03-06Referred to the Subcommittee on Health.
2019-03-06Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-03-06Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-03-06Introduced in House
2019-03-06Introduced in House

CRS Summary

As of 2020-12-09 (53)

Removing Barriers to Colorectal Cancer Screening Act of 2020

This bill modifies cost-sharing requirements for colorectal cancer screening tests, and drug manufacturer reporting requirements, under Medicare medical services.

Specifically, the bill waives coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure. The bill phases in implementation over an eight-year period.

Additionally, manufacturers of covered drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

Cosponsors (20)

Rodney Davis (R-IL)
A. McEachin (D-VA)
David McKinley (R-WV)
Nanette Barragan (D-CA)
SANFORD BISHOP (D-GA)
Brendan Boyle (D-PA)
Julia Brownley (D-CA)
David Cicilline (D-RI)
Joe Courtney (D-CT)
PETER DEFAZIO (D-OR)
ROSA DELAURO (D-CT)
Theodore Deutch (D-FL)
Debbie Dingell (D-MI)
ELIOT ENGEL (D-NY)
Dwight Evans (D-PA)
Bill Foster (D-IL)
Tulsi Gabbard (D-HI)
Ruben Gallego (D-AZ)
John Garamendi (D-CA)
Raúl Grijalva (D-AZ)

Subjects

Cancer
Digestive and metabolic diseases
Medical tests and diagnostic methods
Medicare

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.